Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Consolidated Statements of Operations (unaudited)
Product revenue, net	$ 0	$ 2,034,113	$ 0	$ 4,140,090
OPERATING EXPENSES
Cost of products sold	0	97,637	0	97,637
Research and development	3,429,479	5,554,200	9,173,233	10,568,830
Selling, general and administrative	1,681,844	3,032,613	3,702,775	6,232,857
Gain on sale of Vyleesi	2,500,000	7,823,482	2,500,000	7,823,482
Total operating expenses	2,611,323	860,968	10,376,008	9,075,842
(Loss) Income from operations	(2,611,323)	1,173,145	(10,376,008)	(4,935,752)
OTHER (EXPENSE) INCOME
Investment income	29,044	62,026	107,620	133,656
Foreign currency transaction (loss) gain	143,600	(306,697)	12,000	(146,947)
Interest expense	(3,803)	(1,605)	(9,743)	(12,487)
Offering expenses	0	(696,912)	0	(696,912)
Change in fair value of warrant liabilities	0	(8,073,991)	0	(7,391,591)
Total other income (expense), net	168,841	(9,017,179)	109,877	(8,114,281)
NET LOSS	$ (2,442,482)	$ (7,844,034)	$ (10,266,131)	$ (13,050,033)
Basic and diluted net loss per common share	$ (0.12)	$ (0.56)	$ (0.51)	$ (0.99)
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share	20,634,887	14,097,757	20,239,997	13,134,228